Between Dec 19, 2024 and Jan 2, 2025, datasets can be submitted to DRUM but will not be processed until after the break. Staff will not be available to answer email during this period, and will not be able to provide DOIs until after Jan 2. If you are in need of a DOI during this period, consider Dryad or OpenICPSR. Submission responses to the UDC may also be delayed during this time.
 

A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer.

Loading...
Thumbnail Image

Persistent link to this item

Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer.

Published Date

2010-10

Publisher

Type

Thesis or Dissertation

Abstract

Purpose: To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer. Patients and Methods: Patients with surgically staged III-IV (excluding IIIA from positive cytology alone) endometrial cancer or biopsy confirmed recurrent disease were eligible. Treatment consisted of 3 cycles of docetaxel (75mg/m2) and carboplatin (AUC 6) on a q21 day schedule followed by involved field irradiation (45Gy) ± brachytherapy and 3 additional cycles of docetaxel and carboplatin. Kaplan-Meier (KM) methods estimated overall survival (OS) and progression free survival (PFS). Results: Forty-two patients enrolled, 7 did not complete therapy. 95% (39/41) had primary disease. Median age = 58 years (range: 21-81). 78% (32/41) = endometrioid histology. Stages=10 IIIA, 21 IIIC, 1 IVA, 7 IVB, (recurrent=1 IC, 1 IIA). There were 23 non-hematologic and 14 grade 3 and 16 grade 4 hematologic toxicities. Five patients died following treatment with a median follow-up of 16.1 months (range: 5-51). KM estimates and 95% confidence intervals for OS at 1 year were=94.4% (79.5-98.6), at 2 years 90.9% (74.2-97.0)), and at 3 years 79.6% (45.4-93.6). Of the 39 with primary disease, 9 progressed or died within 3 years of study enrollment. KM estimates and 95% confidence intervals for PFS at 1 year were 85.7% (69.0-93.8), at 2 years 75.6% (56.8-87.1), and at 3 years=68.0% (44.6-83.2). Conclusions: “Sandwiching” radiation between chemotherapy for advanced or recurrent endometrial cancer merits further development based on the reported PFS and OS.

Description

University of Minnesota M.S. thesis. October 2010. Major: Clinical Research. Advisor: Linda F. Carson, M.D. 1 computer file (PDF); vi, 31 pages.

Related to

Replaces

License

Series/Report Number

Funding information

Isbn identifier

Doi identifier

Previously Published Citation

Other identifiers

Suggested citation

Geller, Melissa Ann MD. (2010). A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer.. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/102941.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.